news

  • 1 April 2014
    InDex Pharmaceuticals and Almirall enter into a license agreement for European rights of the phase III drug candidate Kappaproct®

    InDex Pharmaceuticals and Almirall announced today that they have signed a license agreement for the European marketing rights to the drug candidate Kappaproct®. Under the terms of the agreement, InDex is eligible for an upfront payment as well as success driven milestone payments with a total deal value that could exceed EUR100M. InDex is also entitled to receive double digit royalties from Almirall on the European net sales of Kappaproct®.

    InDex Pharmaceutical's lead drug candidate Kappaproct® is a DNA-based immunomodulatory sequence (DIMS) that targets the toll-like receptor 9 (TLR9). Kappaproct is a potential treatment for severe Ulcerative Colitis (UC), a debilitating, chronic inflammation of the large intestine. The results from the ongoing Phase III trial COLLECT are expected in mid-2014.

    "Almirall has extensive sales and marketing experience within the gastrointestinal field in Europe. Moreover, they have a recent track record of success in launching innovative biotechnology products. Thus, Almirall is a perfect partner for InDex in our mission to bring Kappaproct® to the market in Europe" said jesper Wiklund, CEO of InDex Pharmaceuticals. "Moreover, during the partnering process it became clear that Almirall and InDex share a commitment to collaboration as a means to pursuing ambitious scientific goals. This makes for a strong cultural fit between our two companies, which is a promising starting point for a partnership."

    Eduardo Sanchiz, CEO of Almirall SA added "Kappaproct® is in a late stage of development and addresses a major unmet medical need in patients with severe ulcerative colitis. We see a significant commercial potential for this first-in-class immunotherapeutic. Kappaproct® also fits well with our focused interest in gastrointestinal diseases and our aim to bring innovative medicines to the patients".